IPO Plus - IPO

Name▼ / Code▼	Industry	Offer Price	Lot Size	Entry Fee	Closing Date	Grey Market Date▼	Listing Date▲
Ldrobot 01236.HK	Advanced hardware and software	24-30	200	6,060.51	2026/05/06	2026/05/08	2026/05/11
IMPACT Therap-B 07630.HK	Biotechnology - Pharmaceuticals	19.75-21.75	200	4,393.88	2026/05/08	2026/05/12	2026/05/13
Metis TechBio-P 07666.HK	Advanced hardware and software	10.5	500	5,302.95	2026/05/08	2026/05/12	2026/05/13

Name▼

Code▼

Industry

Offer Price

Lot Size

Entry Fee

Closing Date

Grey Market Date▼

Listing Date▲

Ldrobot
01236.HK

Advanced hardware and software

24-30

200

6,060.51

2026/05/06

2026/05/08

2026/05/11

IMPACT Therap-B
07630.HK

Biotechnology - Pharmaceuticals

19.75-21.75

200

4,393.88

2026/05/08

2026/05/12

2026/05/13

Metis TechBio-P
07666.HK

Advanced hardware and software

10.5

500

5,302.95

2026/05/08

2026/05/12

2026/05/13

Summary

Founded in 2009, we are a commercial-stage biotechnology company focused on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally, delivering innovative treatments to address the unmet medical needs of cancer patients. As of the Latest Practicable Date, our pipeline consisted of (i) one self-developed Core Product, senaparib, which has been commercialized in China in January 2025 as a first-line (1L) maintenance therapy for ovarian cancer (OC) across all patient populations regardless of mutation status and is also being evaluated for additional indications, including as monotherapy in advanced OC patients with breast cancer susceptibility gene (BRCA) mutations who have received at least second-line (2L) standard systemic therapy, with Phase II completed, as combination therapy in small cell lung cancer (SCLC) patients in Phase II, and as combination therapy in PARP inhibitor-treated OC patients in Phase Ib and (ii) eleven other self-developed drug candidates (including four clinical-stage and seven preclinical candidates), encompassing emerging modalities such as novel antibody-drug conjugates (ADCs) and degrader candidates. WE MAY NOT BE ABLE TO SUCCESSFULLY DEVELOP AND/OR MARKET OUR CORE PRODUCT FOR ADDITIONAL INDICATIONS. SYNTHETIC LETHALITY SL describes a situation in which simultaneous defects in two pathways lead to cell death, whereas a defect in either pathway alone does not. Compared to conventional cancer treatment modalities, SL-based therapies offer several inherent advantages, including the ability to address “undruggable” targets and resistance and create synergistic combination therapies. SL strategies can be applied in combination with existing standard of care to enhance efficacy, as well as with emerging modalities such as ADCs and radionuclide-drug conjugates (RDCs), to improve precision, reduce off-target toxicity, and expand the therapeutic window. SL represents a clinically validated and high-potential frontier in oncology. The PARP1/2 inhibitors have validated SL as a powerful therapeutic approach, demonstrating both clinical efficacy and strong commercial traction. The potential of the SL field is reflected in the growing industry momentum, driven by the identification of new SL pairs in cancer cells, such as ATR, USP1, PKMYT1, PRMT5 and MAT2A, and further accelerated by increasing investment across the sector. Source: IMPACT Therap-B (07630) Prospectus (IPO Date : 2026/05/05)
Listing Market	MAIN
Industry	Biotechnology - Pharmaceuticals
Background	H Shares
Major Business Area	China

Corporate Information

Substantial Shareholders	Yi SHI (Total share: 13.93%); (H share: 13.93%) Fei CHEN (Total share: 11.79%); (H share: 11.79%) Xiangmin Cui (Total share: 8.53%); (H share: 8.53%) Tencent Holdings Limited (Total share: 7.01%); (H share: 7.01%)
Directors	Cong XU (Chairman and Non-Executive Director) Ning MA (Senior Vice President and Executive Director) Ye Edward TIAN (Executive Vice President and Chief Scientific Officer and Executive Director) Sui Xiong CAI (Chief Executive Officer and Executive Director) Qiang XU (Non-Executive Director) Tao LIU (Non-Executive Director) Chi Hung SIU (Independent Non-Executive Director) Edward Ming GUO (Independent Non-Executive Director) Liming SHAO (Independent Non-Executive Director)
Company Secretary	Yifan HAN Yip Chui Mei
Principal Bankers	China Merchants Bank Co., Ltd.
Solicitors	JunHe LLP Cooley HK
Auditors	Ernst & Young
Registered Office	40/F, Dah Sing Financial Centre, 248 Queen’s Road East, Wanchai, Hong Kong
Share Registrars	Computershare Hong Kong Investor Services Ltd. [Tel: (852) 2862-8628]
Share Registrars Tel No	(852) 2862-8628
Internet Address	http:// www.impacttherapeutics.com
Email Address	IR@impacttherapeutics.com
Tel No	(86 021) 6841-1121
Fax No

Real-time Futures	IPO Plus	Company Announcement
Top 20	Highs/ Lows	Company Dividend
Local Indices	DTDC RMB Traded Stocks	Result Announ. Schedule
World Indices	BioTech Stocks	Research Report
China Indices	Second Listing Stocks	Result Announ. News
Index Constituents	Short Selling	Corp. Event Search
H Shares (All)	ADR	Economic Calendar
Red Chips (All)	A+H+ADR	Economic Database
GEM (All)	A+H	Economic Data Chart
Industries	Shareholding Disclosures	World Interest Rates